Sirolimus for solid organ transplantation in children

Pediatric Transplantation

Volumn 9, Issue 3, 2005, Pages 269-276

  Gupta, Puneet ^a   Kaufman, Stuart ^a   Fishbein, Thomas M ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Immunosuppression; Pediatric transplantation; Sirolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ANEMIA; AREA UNDER THE CURVE; ARTERY THROMBOSIS; BONE MARROW SUPPRESSION; CHALAZION; CHILD; CHRONIC GRAFT REJECTION; DOSE RESPONSE; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; FOURNIER GANGRENE; GRAFT SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HEPATIC ARTERY THROMBOSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVER GRAFT REJECTION; NEPHROTOXICITY; NEUTROPENIA; ORGAN TRANSPLANTATION; PYREXIA IDIOPATHICA; REVIEW; SEPSIS; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT;

CHILD; GRAFT REJECTION; GRAFT VS HOST DISEASE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; SIROLIMUS; TRANSPLANTATION IMMUNOLOGY;

EID: 20344373945     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00305.x     Document Type: Review

References (56)

1. MAGEE JC, BUCUVALAS JC, FARMER DG, HARMON WE, HULBERT-SHEARON TE, MENDELOFF EN. Pediatric transplantation. Am J Transplant 2004: 4(Suppl. 9): 54-71.
2. MARTIN SR, ATKISON P, ANAND R, LINDBLAD AS. Studies of pediatric liver transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Pediatr Transplant 2004: 8: 273-283.
3. SEHGAL SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003: 35(Suppl. 3): 7S-14S.
4. ABRAHAM RT, WIEDERRECHT GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996: 14: 483-510.
5. SCHMIDBAUER G, HANCOCK WW, WASOWSKA B, BADGER AM, KUPIEC-WEGLINSKI JW. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion. Transplantation 1994: 57: 933-941.
6. CAO W, MOHACSI P, SHORTHOUSE R, PRATT R, MORRIS RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995: 59: 390-395.
7. Kuo CJ, CHUNG J, FIORENTINO DF, FLANAGAN WM, BLENIS J, CRABTREE GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992: 358: 70-73.
8. ABRAHAM RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998: 10: 330-336.
9. CAMARDO J. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplant Proc 2003: 35(Suppl. 3): 18S-24S.
10. SHAPIRO AM, LAKEY JR, RYAN EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000: 343: 230-238.
11. MCALISTER VC, GAO Z, PELTEKIAN K, DOMINGUES J, MAHALATI K, MACDONALD AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000: 355: 376-377.
12. PELTEKIAN K, MCALISTER VC, COLOHAN S, et al. De novo use of low-dose tacrolimus and sirolimus in liver transplantation. Transplant Proc 2001: 33: 1341.
13. GROTH CG, BACKMAN L, MORALES JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999: 67: 1036-1042.
14. ZIMMERMAN JJ, KAHAN BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997: 37: 405-415.
15. ZIMMERMAN JJ, HARPER D, GETSY J, JUSKO WJ. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol 2003: 43: 1168-1176.
16. ETTENGER RB, GRIMM EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001: 38(Suppl. 2): S22-S28.
17. SINDHI R, WEBBER S, VENKATARAMANAN R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001: 72: 851-855.
18. SCHACHTER AD, MEYERS KE, SPANEAS LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004: 8: 171-177.
19. TEJANI A, ALEXANDER S, ETTENGER R, et al. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant 2004: 8: 151-160.
20. SCHUBERT M, VENKATARAMANAN R, HOLT DW, et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 2004: 4: 767-773.
21. SINDHI R. Sirolimus in pediatric transplant recipients. Transplant Proc 2003: 35(Suppl. 3): 113S-114S.
22. MUTHUKKUMAR S, RAMESH TM, BONDADA S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995: 60: 264-270.
23. NEPOMUCENO RR, BALATONI CE, NATKUNAM Y, SNOW AL, KRAMS SM, MARTINEZ OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003: 63: 4472-4480.
24. STRAATMAN LP, COLES JG. Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplantation 2000: 70: 541-543.
25. HORSLEN S, TORRES C, COLLIER D, et al. Initial experience using rapamycin immunosuppression in pediatric intestinal transplant recipients. Transplant Proc 2002: 34: 934-935.
26. PAPPAS PA, WEPPLER D, PINNA AD, et al. Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transplant 2000: 4: 45-49.
27. NISHIDA S, PINNA A, VERZARO R, et al. Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation. Transplant Proc 2001: 33: 1495.
28. KAHAN BD, PODBIELSKI J, NAPOLI KL, KATZ SM, MEIER-KRIESCHE HU, VAN BUREN CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998: 66: 1040-1046.
29. KAHAN BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000: 356: 194-202.
30. SWANSON SJ, HALE DA, MANNON RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002: 360: 1662-1664.
31. ROBERTSON RP. Islet transplantation as a treatment for diabetes - a work in progress. N Engl J Med 2004: 350: 694-705.
32. MCALISTER VC, PELTEKIAN KM, MALATJALIAN DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001: 7: 701-708.
33. DUNKELBERG JC, TROTTER JF, WACHS M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003: 9: 463-468.
34. FUNG J, MARCOS A. Rapamycin: friend, foe, or misunderstood? Liver Transpl 2003: 9: 469-472.
35. VILALTA R, VILA A, NIETO J, CALLIS L. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation. Transplant Proc 2003: 35: 703-704.
36. EL-SABROUT R, WEISS R, BUTT F, et al. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients. Transplant Proc 2002: 34: 1942-1943.
37. EL-SABROUT R, WEISS R, BUTT F, et al. Improved lipid profile and blood sugar control in pediatric renal transplant recipients using sirolimus-tacrolimus combination. Transplant Proc 2002: 34: 1946-1947.
38. SINDHI R, GANJOO J, McGHEE W, MAZARIEGOS G, REYES J. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants. Transplant Proc 2002: 34: 1972-1973.
39. FISHBEIN TM, FLORMAN S, GONDOLESI G, et al. Intestinal transplantation before and after the introduction of sirolimus. Transplantation 2002: 73: 1538-1542.
40. MEIER-KRIESCHE HU, KAPLAN B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin Ther 2000: 22 (Suppl. B): B93-B100.
41. CHUEH SC, KAHAN BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003: 76: 375-382.
42. MORRISETT JD, ABDEL-FATTAH G, KAHAN BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003: 35 (Suppl. 3): 143S-150S.
43. DOMINGUEZ J, MAHALATI K, KIBERD B, MCALISTER VC, MACDONALD AS. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000: 70: 1244-1247.
44. MIGITA K, EGUCHI K, AOYAGI T, et al. The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast. Clin Exp Immunol 1996: 104: 86-91.
45. VALENTE JF, HRICIK D, WEIGEL K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003: 3: 1128-1134.
46. TROPPMANN C, PIERCE JL, GANDHI MM, GALLAY BJ, McViCAR JP, PEREZ RV. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003: 76: 426-429.
47. KING-BIGGS MB, DUNITZ JM, PARK SJ, KAY SAVIK S, HERTZ MI. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003: 75: 1437-1443.
48. GUILBEAU JM. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002: 36: 1391-1395.
49. HAYDAR AA, DENTON M, WEST A, REES J, GOLDSMITH DJ. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 2004: 4: 137-139.
50. MORELON E, STERN M, KREIS H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000: 343: 225-226.
51. AVITZUR Y, JIM ENEZ-RIVERA C, FECTEAU A, JONES N, NGAN BY, NG VL. Interstitial granulomatous pneumonitis associated with sirolimus in a child after liver transplantation. J Pediatr Gastroenterol Nutr 2003: 37: 91-94.
52. LAWSIN L, LIGHT JA. Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. Transplantation 2003: 75: 157-160.
53. ROBSON M, COTE I, ABBS I, KOFFMAN G, GOLDSMITH D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003: 3: 324-327.
54. PARAMESH AS, GROSSKREUTZ C, FLORMAN SS, et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 2004: 77: 129-148.
55. LANGER RM, VAN BUREN CT, KATZ SM, KAHAN BD. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 2002: 73: 756-760.
56. FLORMAN S, BENCHIMOL C, LIEBERMAN K, BURROWS L, BROMBERG JS. Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen. Pediatr Transplant 2002: 6: 352-355.